| Medical and Health Sciences | Lifetime | 190 | AT 2 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 201 | AT 3 | 99.96 |
| Surgery | Lifetime | 18 | AT 1 | 99.98 |
| Pulmonary and Respiratory Medicine | Lifetime | 39 | AT 1 | 99.95 |
| Urology | Lifetime | 21 | AT 1 | 99.72 |
| Oncology | Lifetime | 396 | AT 2 | 99.33 |
| Cancer Research | Lifetime | 463 | AT 2 | 97.12 |
| Rheumatology | Lifetime | 655 | AT 8 | 96.75 |
| Surgery | 2021-2025 | 12 | AT 1 | 99.93 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 60 | AT 1 | 99.73 |
| Oncology | 2021-2025 | 168 | AT 2 | 98.72 |
| Urology | 2021-2025 | 32 | AT 1 | 97.48 |
| Rheumatology | 2021-2025 | 347 | AT 8 | 87.15 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 836 | AT 5 | 79.33 |
| Cancer Research | 2021-2025 | 406 | AT 2 | 70.52 |
| Bladder and Urothelial Cancer Treatments | Lifetime | 1 | AT 1 | 99.96 |
| Urinary and Genital Oncology Studies | Lifetime | 1 | AT 1 | 99.97 |
| Urological Disorders and Treatments | Lifetime | 2 | AT 1 | 99.97 |
| Ferroptosis and cancer prognosis | Lifetime | 6 | AT 1 | 99.75 |
| Prostate Cancer Diagnosis and Treatment | Lifetime | 12 | AT 1 | 99.92 |
| Prostate Cancer Treatment and Research | Lifetime | 18 | AT 1 | 99.89 |
| Infectious Disease Case Reports and Treatments | Lifetime | 1 | AT 1 | 99.62 |
| Renal cell carcinoma treatment | Lifetime | 21 | AT 1 | 99.80 |
| Cancer, Lipids, and Metabolism | Lifetime | 47 | AT 1 | 99.74 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 17 | AT 2 | 98.93 |
| Urologic and reproductive health conditions | Lifetime | 24 | AT 1 | 99.76 |
| Esophageal Cancer Research and Treatment | Lifetime | 57 | AT 1 | 99.49 |
| Multiple and Secondary Primary Cancers | Lifetime | 37 | AT 1 | 99.47 |
| Cancer Research and Treatments | Lifetime | 88 | AT 1 | 99.28 |
| Colorectal Cancer Screening and Detection | Lifetime | 96 | AT 1 | 99.46 |
| Renal and related cancers | Lifetime | 179 | AT 1 | 98.98 |
| Urinary Bladder and Prostate Research | Lifetime | 167 | AT 4 | 98.86 |
| Epigenetics and DNA Methylation | Lifetime | 651 | AT 7 | 98.47 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 636 | AT 4 | 98.60 |
| Genital Health and Disease | Lifetime | 317 | AT 3 | 97.25 |
| Economic and Financial Impacts of Cancer | Lifetime | 636 | AT 3 | 94.06 |
| Ureteral procedures and complications | Lifetime | 729 | AT 7 | 93.15 |
| Statistical Methods in Clinical Trials | Lifetime | 797 | AT 8 | 92.54 |
| Abdominal Trauma and Injuries | Lifetime | 887 | AT 12 | 90.43 |
| Nephrotoxicity and Medicinal Plants | Lifetime | 699 | AT 4 | 69.81 |
| Urological Disorders and Treatments | 2021-2025 | 2 | AT 1 | 99.80 |
| Bladder and Urothelial Cancer Treatments | 2021-2025 | 5 | AT 1 | 99.89 |
| Urinary and Genital Oncology Studies | 2021-2025 | 5 | AT 1 | 99.88 |
| Prostate Cancer Diagnosis and Treatment | 2021-2025 | 15 | AT 1 | 99.65 |
| Prostate Cancer Treatment and Research | 2021-2025 | 43 | AT 1 | 99.48 |
| Renal cell carcinoma treatment | 2021-2025 | 32 | AT 1 | 99.30 |
| Infectious Disease Case Reports and Treatments | 2021-2025 | 1 | AT 1 | 97.20 |
| Urologic and reproductive health conditions | 2021-2025 | 22 | AT 1 | 97.53 |
| Esophageal Cancer Research and Treatment | 2021-2025 | 130 | AT 1 | 96.92 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 506 | AT 1 | 98.04 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 42 | AT 1 | 94.50 |
| Renal and related cancers | 2021-2025 | 126 | AT 2 | 95.94 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 107 | AT 3 | 92.10 |
| Urinary Bladder and Prostate Research | 2021-2025 | 150 | AT 2 | 95.24 |
| Colorectal Cancer Screening and Detection | 2021-2025 | 382 | AT 1 | 94.38 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 393 | AT 3 | 90.88 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 461 | AT 8 | 91.49 |
| Genital Health and Disease | 2021-2025 | 226 | AT 4 | 88.53 |
| Urinary Tract Infections Management | 2021-2025 | 359 | AT 1 | 87.17 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 521 | AT 2 | 87.83 |
| Ureteral procedures and complications | 2021-2025 | 206 | AT 2 | 85.13 |
| Global Cancer Incidence and Screening | 2021-2025 | 993 | AT 2 | 87.41 |
| Pelvic floor disorders treatments | 2021-2025 | 838 | AT 9 | 85.86 |
| Renal and Vascular Pathologies | 2021-2025 | 634 | AT 4 | 80.33 |
| Hormonal and reproductive studies | 2021-2025 | 610 | AT 2 | 80.63 |
| Cancer Research and Treatments | 2021-2025 | 963 | AT 1 | 78.15 |
| Testicular diseases and treatments | 2021-2025 | 424 | AT 4 | 74.03 |
| Statistical Methods in Clinical Trials | 2021-2025 | 693 | AT 5 | 73.54 |
| Sexual Differentiation and Disorders | 2021-2025 | 877 | AT 7 | 68.09 |
| Fibroblast Growth Factor Research | 2021-2025 | 753 | AT 5 | 61.33 |
| Medical History and Research | 2021-2025 | 81 | AT 4 | 47.40 |
